

BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida

NEW YORK, Jan. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits, CEO will provide a corporate overview presentation at the NobleCon15 Investor Conference in Fort Lauderdale, Florida. Ralph Kern M.D, MHSc, Chief Operating Officer and Chief Medical Officer will also participate in a panel discussion focused on drug development advances in neurodegenerative disease, including: (1) unmet need, (2) patient selection, (3) enrichment strategies to decrease heterogeneity and (4) practical use of biomarkers and cognitive testing.

NobleCon15 is being held on Monday and Tuesday, January 28-29, 2019 at the W Hotel in Fort Lauderdale, Florida. Webcast will be available on Tuesday, January 29, 2019 on BrainStorm's website www.brainstorm-cell.com, NobleCon15 website www.nobleconference.com, and Channelchek portal www.channelchek.com. Webcast will be archived for 90 days.

2019 NobleCon15 Conference Details:

Date: Monday, January 28, 2019
Presenter: Chaim Lebovits, CEO
Presentation Time: 12:30 PM Eastern Standard Time
Location: Studio 2 at the W Hotel in Fort Lauderdale, Florida
Webcast: <https://goo.gl/LD9JLE>

Panelist: Ralph Kern MD, MHSc, COO & CMO
Panel Discussion: 5:30 PM Eastern Standard Time
Location: Studio 1 at the W Hotel in Fort Lauderdale, Florida

Meetings

BrainStorm senior management will also be hosting institutional investor meetings at the 2019 NobleCon15 Conference. Please use the Investor contact information provided below to schedule a meeting.

About NurOwn®

NurOwn® (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm is currently conducting a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis (MS) and plans to start enrollment in early 2019.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm is currently enrolling a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. For more information, visit BrainStorm's website at www.brainstorm-cell.com.

About Noble Capital Markets, Inc.

Noble Capital Markets is an equity-research driven, full-service, investment & merchant banking boutique focused on emerging growth companies. In addition to NobleCon, Noble hosts numerous "non-deal" corporate road shows across the United States and Canada. In late 2018, Noble launched Channelchek.com which features advanced market data, institutional-quality research, balanced news, videos and podcasts covering more than 6,000 emerging growth companies. Members: FINRA, SIPC,

MSRB. www.noblecapitalmarkets.com.

Safe-Harbor Statements

Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at <http://www.sec.gov>. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Media:


Joseph Petroziello
BrainStorm Cell Therapeutics
Phone: +1.215.485.6797
Email: JP@brainstorm-cell.com

Investors:

Marcy Beth Nanus
Solebury Trout
Phone: +1.646.378.2927
Email: MNanus@troutgroup.com



BrainStorm Cell Therapeutics Inc.

Additional assets available online:  [Photos \(1\)](#)

<https://ir.brainstorm-cell.com/2019-01-25-BrainStorm-Cell-Therapeutics-to-Present-at-the-2019-NobleCon15-Annual-Investor-Conference-in-Fort-Lauderdale-Florida>